Pharmaceuticals, Biotechnology and Life Sciences
NEW YORK–(BUSINESS WIRE)–Schrödinger today announced receipt of a milestone payment from Sanofi (EURONEXT: SAN, NASDAQ: SNY) to mark the advancement…
CAMBRIDGE, England–(BUSINESS WIRE)–Metrion Biosciences (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of…
Indivior’s “Recover” study found that 75% of patients who had received 12 once-monthly doses of sublocade in a Phase 3 clinical trial were abstinent from illicit opioids for a year after the study ended. In this observational study, abstinence was defined as self-report confirmed by urine drug screen.
Mallinckrodt’s retrospective study has shown the effectiveness of Extracorporeal Photopheresis (ECP), as an adjunct to local standard therapy, in lung transplant recipients with Bronchiolitis Obliterans Syndrome (BOS).
Myriad Genetics, AstraZeneca, and Merck have expanded their companion diagnostic collaboration, to use BRACAnalysis CDx to identify germline BRCA mutations in…
Roche presents data from a mock clinical trial study suggesting that next-generation discovery proteomics is ready for use in clinical…
WALTHAM, Mass.–(BUSINESS WIRE)–Sobi, an international biopharmaceutical company transforming the lives of people affected by rare diseases, announced that investigators will…
PRIME (PRIority MEdicines) designation based on clinical study results evaluating safety and efficacy of novel CAR-T therapy in the treatment…
Belgian Oxurion has enrolled 70 patients for Phase 2 testing of its THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of Diabetic Macular Edema (DME).
Sandoz is resubmitting its Biologics License Application for a proposed biosimilar pegfilgrastim to the US FDA